Risk-adapted therapy for advanced-stage natural killer/T-cell lymphoma: An analysis from the China Lymphoma Collaborative Group Study.

Weiping Liu,Yong Yang,Shunan Qi,Ying Wang,Xia He,G. Wu,Baolin Qu,Liting Qian,Fuquan Zhang,Xue-Ying Qiao,Wang Hua,Gaofeng Li,Yujing Zhang,Yuan Zhu,Jianzhong Cao,Junxin Wu,Tao Wu,Jun Zhu,Yexiong Li,Yuqin Song

Risk-adapted therapy for advanced-stage natural killer/T-cell lymphoma: An analysis from the China Lymphoma Collaborative Group Study.

2020

Weiping Liu
Yong Yang
Shunan Qi
Ying Wang
Xia He
G. Wu
Baolin Qu
Liting Qian
Fuquan Zhang
Xue-Ying Qiao
Wang Hua
Gaofeng Li
Yujing Zhang
Yuan Zhu
Jianzhong Cao
Junxin Wu
Tao Wu
Jun Zhu
Yexiong Li
Yuqin Song

e20041Background: Few studies focused on the risk-adapted therapy for advanced-stage natural killer/T-cell lymphoma (NKTCL) due to poor prognosis. Methods: Data of 406 patients with advanced-stage ...

Keywords:

Oncology
advanced stage
collaborative group
Pathology
Natural killer T cell
Lymphoma
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations